B8FK Stock Overview
A biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Biofrontera AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.23 |
| 52 Week High | €12.18 |
| 52 Week Low | €2.15 |
| Beta | 0.42 |
| 1 Month Change | -17.59% |
| 3 Month Change | -3.47% |
| 1 Year Change | -73.71% |
| 3 Year Change | -93.27% |
| 5 Year Change | -97.71% |
| Change since IPO | -99.31% |
Recent News & Updates
Recent updates
Biofrontera AG (ETR:B8FK) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Oct 13
Biofrontera AG (ETR:B8FK) Not Doing Enough For Some Investors As Its Shares Slump 47%
May 21Why Investors Shouldn't Be Surprised By Biofrontera AG's (ETR:B8F) 30% Share Price Plunge
Mar 07We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn Rate
Feb 19Here's Why It's Unlikely That Biofrontera AG's (ETR:B8F) CEO Will See A Pay Rise This Year
Dec 07Does Biofrontera (ETR:B8F) Have A Healthy Balance Sheet?
Jun 08Biofrontera AG (ETR:B8F) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Apr 14Shareholder Returns
| B8FK | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -9.2% | -2.5% | -2.6% |
| 1Y | -73.7% | -15.6% | 6.9% |
Return vs Industry: B8FK underperformed the German Pharmaceuticals industry which returned -15.6% over the past year.
Return vs Market: B8FK underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| B8FK volatility | |
|---|---|
| B8FK Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: B8FK's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: B8FK's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 78 | n/a | www.biofrontera.com |
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin.
Biofrontera AG Fundamentals Summary
| B8FK fundamental statistics | |
|---|---|
| Market cap | €13.52m |
| Earnings (TTM) | -€357.00k |
| Revenue (TTM) | €18.17m |
0.7x
P/S Ratio-37.9x
P/E RatioIs B8FK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B8FK income statement (TTM) | |
|---|---|
| Revenue | €18.17m |
| Cost of Revenue | €4.85m |
| Gross Profit | €13.32m |
| Other Expenses | €13.68m |
| Earnings | -€357.00k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 30, 2025
| Earnings per share (EPS) | -0.059 |
| Gross Margin | 73.31% |
| Net Profit Margin | -1.96% |
| Debt/Equity Ratio | 0% |
How did B8FK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:50 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biofrontera AG is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raymond Myers | Benchmark Company |
| Navid Malik | Cavendish Historical (Cenkos Securities) |
| Robert Wasserman | Dawson James Securities |